Intra Cellular Therapies | ITCI - Sales Revenues


Intra Cellular Therapies reported $199.22M in Sales Revenues for its fiscal quarter ending in December of 2024.



Sales Change Date
Acadia Pharmaceuticals USD 278.6M 14M Sep/2025
ALKERMES USD 394.2M 3.5M Sep/2025
BioCryst Pharmaceuticals USD -86.95M 204.03M Dec/2024
Biogen USD 2.28B 250M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Cytokinetics USD 1.93M 64.83M Sep/2025
Esperion Therapeutics USD 51.63M 22.2M Sep/2024
Gilead Sciences USD 7.93B 130M Dec/2025
Halozyme Therapeutics USD 354M 148M Sep/2025
J&J USD 24.6B 610M Dec/2025
Minerva Neurosciences USD 0 0 Sep/2024
Nektar Therapeutics USD 24.12M 635K Sep/2024
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Novartis USD 14.36B 478M Sep/2025
Prothena USD 2.42M 2M Sep/2025
RedHill Biopharma USD 1.29M 722K Jun/2024
Supernus Pharmaceuticals USD 192.1M 26.6M Sep/2025
United Therapeutics USD 799.5M 900K Sep/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024